12/1
07:44 am
alt
Altimmune announces CEO transition [Seeking Alpha]
Medium
Report
Altimmune announces CEO transition [Seeking Alpha]
12/1
07:30 am
alt
Altimmune Announces CEO Transition and Succession Plan
Medium
Report
Altimmune Announces CEO Transition and Succession Plan
11/26
07:53 am
alt
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
07:30 am
alt
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/12
08:46 am
alt
Altimmune (NASDAQ:ALT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Altimmune (NASDAQ:ALT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/11
09:21 am
alt
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
Low
Report
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
11/11
08:51 am
alt
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
Low
Report
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
11/7
09:27 am
alt
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
Medium
Report
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
11/7
08:41 am
alt
Altimmune (NASDAQ:ALT) had its price target lowered by analysts at Citizens Jmp from $15.00 to $14.00. They now have a "market outperform" rating on the stock.
Medium
Report
Altimmune (NASDAQ:ALT) had its price target lowered by analysts at Citizens Jmp from $15.00 to $14.00. They now have a "market outperform" rating on the stock.
11/7
08:05 am
alt
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
Medium
Report
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
11/6
07:00 am
alt
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
Medium
Report
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
11/5
07:30 am
alt
Altimmune to Participate in Two Upcoming Investor Conferences
Low
Report
Altimmune to Participate in Two Upcoming Investor Conferences
11/3
07:30 am
alt
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
Low
Report
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
10/30
07:30 am
alt
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Low
Report
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
10/20
08:08 am
alt
Altimmune (NASDAQ:ALT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Altimmune (NASDAQ:ALT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
10/20
07:30 am
alt
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
Medium
Report
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
10/16
10:16 am
alt
Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
Medium
Report
Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
10/10
08:06 am
alt
Altimmune (NASDAQ:ALT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Altimmune (NASDAQ:ALT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
10/8
06:10 pm
alt
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/7
07:24 am
alt
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Low
Report
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10/6
04:49 pm
alt
Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT
Low
Report
Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT
10/6
01:58 pm
alt
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Low
Report
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
10/6
10:09 am
alt
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline
Medium
Report
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline
10/6
08:45 am
alt
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders
Low
Report
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders
10/5
11:40 pm
alt
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Low
Report
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune